{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:18:09Z","timestamp":1768796289993,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T00:00:00Z","timestamp":1439942400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12874-015-0047-5","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T11:10:14Z","timestamp":1439896214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods"],"prefix":"10.1186","volume":"15","author":[{"given":"Abdalla","family":"Aly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberechukwu","family":"Onukwugha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Daniel","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Balakumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,19]]},"reference":[{"issue":"4","key":"47_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrendo.2010.227","volume":"7","author":"LJ Suva","year":"2011","unstructured":"Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7(4):208\u201318.","journal-title":"Nat Rev Endocrinol"},{"issue":"16","key":"47_CR2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655\u201364.","journal-title":"N Engl J Med"},{"issue":"20 Pt 2","key":"47_CR3","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s\u20139.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"47_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","volume":"15","author":"V DePuy","year":"2007","unstructured":"DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15(7):869\u201376.","journal-title":"Support Care Cancer"},{"issue":"2","key":"47_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/pme.12016","volume":"14","author":"M Zhu","year":"2013","unstructured":"Zhu M, Liang R, Pan LH, Huang B, Qian W, Zhong JH, et al. Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials. Pain Med. 2013;14(2):257\u201364.","journal-title":"Pain Med"},{"issue":"16","key":"47_CR6","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082\u201392.","journal-title":"Eur J Cancer"},{"issue":"4","key":"47_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579\u201384.","journal-title":"Ann Oncol"},{"key":"47_CR8","unstructured":"Anonymous Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Silver Spring, Maryland, USA: Food and Drug Administration (FDA); 2007."},{"issue":"4","key":"47_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1200\/JCO.2013.53.9528","volume":"32","author":"AV D\u2019Amico","year":"2014","unstructured":"D\u2019Amico AV. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol. 2014;32(4):362\u20134.","journal-title":"J Clin Oncol"},{"issue":"4","key":"47_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jval.2010.11.014","volume":"14","author":"J Felix","year":"2011","unstructured":"Felix J, Andreozzi V, Soares M, Borrego P, Gervasio H, Moreira A, et al. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health. 2011;14(4):499\u2013505.","journal-title":"Value Health"},{"issue":"1","key":"47_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/pcan.2012.42","volume":"16","author":"M Hagiwara","year":"2013","unstructured":"Hagiwara M, Delea TE, Saville MW, Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16(1):23\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"47_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1748-717X-7-168","volume":"7","author":"G Hess","year":"2012","unstructured":"Hess G, Barlev A, Chung K, Hill JW, Fonseca E. Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer. Radiat Oncol. 2012;7:168.","journal-title":"Radiat Oncol"},{"issue":"5","key":"47_CR13","first-page":"317","volume":"14","author":"MJ Lage","year":"2008","unstructured":"Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008;14(5):317\u201322.","journal-title":"Am J Manag Care"},{"issue":"1","key":"47_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/pcan.2010.49","volume":"14","author":"NV Velde","year":"2011","unstructured":"Velde NV, Wu EQ, Guo A, Lu M, Yu AP, Sharma H, et al. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. Prostate Cancer Prostatic Dis. 2011;14(1):79\u201384.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"47_CR15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.18553\/jmcp.2010.16.9.693","volume":"16","author":"A Barlev","year":"2010","unstructured":"Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm. 2010;16(9):693\u2013702.","journal-title":"J Manag Care Pharm"},{"issue":"2","key":"47_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40273-013-0121-y","volume":"32","author":"J Jayasekera","year":"2014","unstructured":"Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. Pharmacoeconomics. 2014;32(2):173\u201391.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"47_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162\u20137.","journal-title":"J Urol"},{"issue":"2","key":"47_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/pcan.2011.7","volume":"14","author":"N Sathiakumar","year":"2011","unstructured":"Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999\u20132006. Prostate Cancer Prostatic Dis. 2011;14(2):177\u201383.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"47_CR19","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1345\/aph.1P152","volume":"44","author":"MM Spence","year":"2010","unstructured":"Spence MM, Hui RL, Chan J, Schottinger JE. Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid. Ann Pharmacother. 2010;44(9):1384\u20138.","journal-title":"Ann Pharmacother"},{"issue":"18 Pt 2","key":"47_CR20","doi-asserted-by":"publisher","first-page":"6397S","DOI":"10.1158\/1078-0432.CCR-040030","volume":"10","author":"A Lipton","year":"2004","unstructured":"Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res. 2004;10(18 Pt 2):6397S\u2013403.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"47_CR21","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150\u20137.","journal-title":"J Clin Oncol"},{"issue":"9768","key":"47_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813\u201322.","journal-title":"Lancet"},{"key":"47_CR23","unstructured":"Anonymous A Profile of Older Americans: 2012. 2012."},{"issue":"11","key":"47_CR24","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s00198-009-0840-2","volume":"20","author":"JR Curtis","year":"2009","unstructured":"Curtis JR, Taylor AJ, Matthews RS, Ray MN, Becker DJ, Gary LC, et al. \u201cPathologic\u201d fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int. 2009;20(11):1969\u201372.","journal-title":"Osteoporos Int"},{"issue":"5","key":"47_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1089\/jpm.2009.9633","volume":"12","author":"N Janjan","year":"2009","unstructured":"Janjan N, Lutz ST, Bedwinek JM, Hartsell WF, Ng A, Pieters Jr RS, et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med. 2009;12(5):417\u201326.","journal-title":"J Palliat Med"},{"key":"47_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CLEP.S5446","volume":"1","author":"AO Jensen","year":"2009","unstructured":"Jensen AO, Norgaard M, Yong M, Fryzek JP, Sorensen HT. Validity of the recorded International Classification of Diseases, 10th edition diagnoses codes of bone metastases and skeletal-related events in breast and prostate cancer patients in the Danish National Registry of Patients. Clin Epidemiol. 2009;1:101\u20138.","journal-title":"Clin Epidemiol"},{"key":"47_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fonc.2012.00215","volume":"2","author":"KA Ahmed","year":"2013","unstructured":"Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2013;2:215.","journal-title":"Front Oncol"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-015-0047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12874-015-0047-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-015-0047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T15:45:26Z","timestamp":1653061526000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-015-0047-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,19]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["47"],"URL":"https:\/\/doi.org\/10.1186\/s12874-015-0047-5","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,19]]},"article-number":"65"}}